The creation of artificial blood is undoubtedly one of the most pressing problems of modern medicine. An unconditional breakthrough in this direction was the research of a group of Scottish scientists from the University of Edinburgh under the leadership of Mark Turner. They have developed a technology for producing artificial blood from stem cells.
Already in 2016, the first trials of artificial blood are planned, in which volunteers suffering from erytoblastic anemia will take part. This choice is far from accidental, since it is these patients who need regular blood transfusions. The "starting" dose is 5 milliliters. With normal absorption, the amount of blood will be increased.
The source of its receipt will be blood cells taken from people with a rare type of blood, which is suitable for almost all patients. If successful, such blood will become more accessible, cheaper, and eventually completely replace donor blood.